Source-grounded facts extracted from EXAGEN INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EXAGEN INC. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
“The Company's stockholders approved, by an advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”
EXAGEN INC. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
EXAGEN INC. shareholders approved Election of Class I Directors at the 2026-06-09 meeting.
“The Company's stockholders elected the following two Class I directors for a three-year term of office expiring at the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until such director's earlier death, resignation or removal.”
EXAGEN INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income Net loss $ (3,967). Guidance reaffirmed.
“Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per”
EXAGEN INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $16,631, net income $(4,673). Guidance initiated.
“and full year ended December 31, 2025, and recent business highlights. Three Months Ended December 31, Year Ended December 31, 2025 2025 (in thousands, except ASP data) Revenue $ 16,631 $ 66,575 Gross margin 55.4 % 58.3 % Operating expenses $ 14,181 $ 52,869 Loss from operations $ (4,975) $ (14,070) Net loss $ (4,673) $ (19,951) Adjusted EBITDA $ (3,670) $”
EXAGEN INC. incurred term loan of up to $75.0 million with Perceptive Credit Holdings IV, LP at greater of (a) Term SOFR ... and (b) 4.75% per annum, plus an applicable margin maturing April 25, 2030.
“On April 25, 2025 (the “Closing Date”), Exagen Inc. (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings IV, LP, as lender and administrative agent (“Perceptive”), which provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $75.0 million (the “Perceptive Term Loan Facility”).”
Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..
“replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.”
John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..
“the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of August 1, 2024.”
Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..
“On July 25, 2024, the Company appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..
“John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi”
Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..
“On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.”
Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..
“On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
EXAGEN INC. reported the quarter ended March 31, 2024 results: revenue $14.4 million, net income $3.4 million. Guidance raised.
“leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: • Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. • Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2%”
EXAGEN INC. reported the quarter and year ended December 31, 2023 results: revenue $13.8 million for the fourth quarter of 2023, net income $5.6 million for the fourth quarter of 2023.
“On March 18, 2024 , the Company reported its financial results for the quarter and year ended December 31, 2023.”
EXAGEN INC. updated its the full year ended December 31, 2023 guidance (reaffirmed).
“Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.”
Mark Hazeltine resigned as Chief Business Officer at EXAGEN INC..
“On December 6, 2023, Mark Hazeltine resigned from his position as the Company’s Chief Business Officer.”
EXAGEN INC. amended Amendment No. 1 to the Sales Agreement with Cowen and Company, LLC valued at up to $50,000,000 (effective 2023-11-17).
“On November 17, 2023, Exagen Inc. (the “Company”) entered into Amendment No. 1 (“Amendment No. 1”) to that certain sales agreement, dated September 15, 2022 (the “Sales Agreement”), by and between the Company and Cowen and Company, LLC (“TD Cowen”) in connection with the continuation of the Company’s at-the-market equity offering program (the “Program”).”
EXAGEN INC. reported the three and nine months ended September 30, 2023 results: revenue $13.4 million, net income $(5.4) million. Guidance reaffirmed.
“Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. • Recognized total revenue of $13.4 million for the third quarter of 2023. • Delivered gross margin of 57.4% for the third quarter of 2023. • AVISE® CTD trailing twelve-month average selling price (ASP) of $320. • Net loss”
EXAGEN INC. entered into Agreement with Liberty Vista, LP and Mindera Corporation valued at $65,000 (effective 2023-10-24).
“On October 24, 2023, the Company entered into an assignment and assumption of the Company's previously executed lease agreement (the "Agreement") with Liberty Vista, LP, formerly known as Geiger Court, LLC (the "Landlord"), and Mindera Corporation ("Mindera").”
EXAGEN INC. reported financial results for six months ended June 30, 2023.
“On August 7, 2023 , the Company reported its financial results for the three and six months ended June 30, 2023.”
EXAGEN INC. reported quarter ended June 30, 2023 results: revenue $14.1 million. Guidance initiated.
“Second Quarter Highlights: • Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022. • Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023. • Achieved gross margin of 54% in the six months ended June 30, 2023. • AVISE® CTD trailing twelve-month”
Paul Kim was appointed as Class II Director at EXAGEN INC..
“the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board.”
EXAGEN INC. shareholders approved Ratification of appointment of BDO USA, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.
“Proposal 2 The Company's stockholders ratified the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions Broker Non-Votes 13,481,521 2,643 25,382 —”
EXAGEN INC. shareholders approved Election of Class I directors for a three-year term expiring at the 2026 annual meeting at the 2023-06-09 meeting.
“Proposal 1 The Company's stockholders elected the following three Class I directors for a three-year term of office expiring at the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified or until such director's earlier death, resignation or removal. Name Votes For Votes Withheld Broker Non-Votes Brian Birk 10,235,097 412,248 2,862,201 Tina S. Nova, Ph.D. 10,515,263 132,082 2,862,201 Ebetuel Pallares, Ph.D. 10,306,011 341,334 2,862,201”
EXAGEN INC. reported the first quarter ended March 31, 2023 results: revenue $11.2 million, net income $7.7 million. Guidance initiated.
“Revenue was $11.2 million for the first quarter of 2023, compared to $10.4 million in the first quarter of 2022, primarily due to an increase in volume which was partially offset by a decrease in ASP. Gross margin was 47.2% in the first quarter of 2023, compared to 44.0% in the first quarter of 2022, primarily due to an increase in AVISE® CTD volume which also resulted in a favorable impact of absorption of COGS and lower royalty expense due to holding claims. Operating expenses were $18.9 million in the first quarter of 2023, compared with $20.1 million in the first quarter of 2022 and $27.3 million in the fourth quarter of 2022, primarily due to decreases in employee related expenses from the reduction in force in early December 2022. For the first quarter of 2023, net loss was $7.7 million, compared to a net loss of $10.3 million for the first quarter of 2022.”
EXAGEN INC. amended Third Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP valued at $10.0 million (effective 2023-04-28).
“On April 28, 2023, Exagen Inc. (the "Company"), entered into the Third Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP ("Innovatus") and the other lenders party thereto (the "Third Loan Amendment"), which amended the term loan agreement, dated as of September 7, 2017, by and among the Company, Innovatus, and other lenders party thereto, as amended on each of November 19, 2019 and October 21, 2021 (the "Original Loan Agreement" and, as amended, the “Loan Agreement”).”
James L.L. Tullis resigned as Director at EXAGEN INC..
“On March 20, 2023, James L.L. Tullis informed the Board of Directors (the 'Board') of Exagen Inc. (the 'Company') that he will resign from the Board effective at the Company's 2023 annual meeting of stockholders.”
EXAGEN INC. reported the year ended December 31, 2022 results: revenue $45.6 million, net income $47.4 million. Guidance raised.
“including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. • Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. • John Aballi, President and CEO, joined the Company in the fourth”
EXAGEN INC. reported the fourth quarter of 2022 results: revenue $12.8 million, net income $14.4 million. Guidance raised.
“of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. • Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. • John Aballi, President and CEO, joined the Company in the fourth quarter of 2022 and implemented a new strategy focused on reducing cash burn”
EXAGEN INC.: Adopted amendment to bylaws to allow Board to appoint an executive chairperson of the Board, who shall also be chairperson of the Board and an officer of the Company, and to empower the executive chairperson to appoint other officers and agents as the business may require (effective 2023-01-19).
“On January 19, 2023, the board of directors (the “Board”) of Exagen Inc. (the “Company”) adopted an amendment (the “Bylaws Amendment”) to the amended and restated bylaws of the Company to provide that the Board may appoint from its members an executive chairperson of the Board and that the executive chairperson, if any, shall also be the chairperson of the Board and an officer of the Company.”
EXAGEN INC. reported preliminary financial results for the year ended December 31, 2022.
“The Company is providing certain preliminary financial information and results of operations for the three months and year ended December 31, 2022, based on currently available information.”
EXAGEN INC. reported preliminary financial results for the three months ended December 31, 2022.
“The Company is providing certain preliminary financial information and results of operations for the three months and year ended December 31, 2022, based on currently available information.”
EXAGEN INC. announced a restructuring with charges of approximately $750,000 (42 employees).
“On December 5, 2022, the Board of Directors of Exagen Inc. (the “Company”) approved a reduction in force intended to conserve the Company’s current cash resources. The Company will reduce its current workforce by 42 employees (the “Reduction in Force”). The Company estimates that it will incur aggregate pre-tax charges of approximately $750,000 in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs.”
Mark Hazeltine was appointed as Chief Business Officer at EXAGEN INC..
“On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer.”
Debra Zack was terminated as Chief Medical Officer at EXAGEN INC..
“On December 5, 2022, Debra Zack, M.D., Ph.D., the Company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.”
EXAGEN INC. reported the quarter ended September 30, 2022 results: revenue $14.7 million, net income $8.1 million. Guidance raised.
“Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: • Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE® CTD test, including AVISE® Lupus, recognized revenue of $12.8 million in the third quarter of 2022. • Delivered 35,569 AVISE® CTD tests, including AVISE® Lupus, in the third quarter of 2022, a 12% increase over the third quarter of 2021. Since the launch of AVISE® CTD in 2012 through the third quarter of 2022, we have delivered over 700,000 of these tests. • Number of ordering healthcare providers totaled 2,287 in the third quarter of 2022, an increase of 16% over the third quarter of 2021. • Medicare resumed reimbursement dating back to Q2 for AVISE Lupus claims. • Increasing full year 2022 revenue guidance, range of $40 million to $43 million.”
EXAGEN INC. reported that prior financial statements should not be relied upon.
“the Company’s financial statements as of and for the three and six months ended June 30, 2022 (the “Non-Reliance Period”) included in the associated Form 10-Q for the period ended June 30, 2022, filed with the Securities Exchange Commission (the “SEC”), (1) should no longer be relied upon due to such errors, and (2) will require restatement.”
Fortunato Ron Rocca resigned as President and Chief Executive Officer at EXAGEN INC..
“Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.”
John Aballi was appointed as President and Chief Executive Officer at EXAGEN INC..
“John Aballi has been appointed as President and Chief Executive Officer of the Company and as a member of the board of directors of the Company”
Ana Hooker was appointed as Director at EXAGEN INC..
“the Board approved an increase in its authorized size from eight members to nine members and appointed Ana Hooker to fill the vacancy created by such increase and serve as a Class II director, with an initial term expiring at the Company's 2024 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.